"2"^^ . . "Treatment of associated anemia in different hematological disorders with epoetin alpha" . "S" . "L\u00E9\u010Dba p\u0159idru\u017Een\u00E9 an\u00E9mie pomoc\u00ED epoetinu alfa u r\u016Fzn\u00FDch hematologick\u00FDch onemocn\u011Bn\u00ED"@cs . . . "1"^^ . "RIV/00216208:11150/04:00004510!RIV08-MSM-11150___" . . "Treatment; associated; anemia; different; hematological; disorders; epoetin; alpha"@en . . "379;384" . "SK - Slovensk\u00E1 republika" . "Tato pr\u00E1ce shrnuje v\u00FDsledky studie proveden\u00E9 za \u00FA\u010Delem ov\u011B\u0159en\u00ED \u00FA\u010Dinnosti l\u00E9\u010Dby epoetinem alfa u pacient\u016F s r\u016Fzn\u00FDmi hematologick\u00FDmi onemocn\u011Bn\u00EDmi a sou\u010Dasn\u011B zhodnocen\u00ED dopadu t\u00E9to l\u00E9\u010Dby na jejich kvalitu \u017Eivota. \u00DA\u010Dinnost l\u00E9\u010Dby byla hodnocena zv\u00FD\u0161en\u00EDm krevn\u00EDch hladin hemoglobinu a spot\u0159ebou substr\u00E1t\u016F erytrocyty pot\u0159ebn\u00FDch ke kontrole anemick\u00E9ho syndromu. Studie byla provedena na 134 pacientech s r\u016Fzn\u00FDmi lymfoproliferativn\u00EDmi onemocn\u011Bn\u00EDmi z nich\u017E 127 bylo monitorov\u00E1no alespo\u0148 3 m\u011Bs\u00EDce v pr\u016Fb\u011Bhu terapie epoetinem alfa. P\u0159\u00EDzniv\u00FD \u00FA\u010Dinek l\u00E9\u010Dby byl viditeln\u00FD u pacient\u016F s mnoho\u010Detn\u00FDm myelomem (85,7%), Waldenstr\u0151movou makroglobulin\u00E9mi\u00ED (80%) a chronickou lymfatickou leuk\u00E9mi\u00ED (76,7%). Naopak, nejni\u017E\u0161\u00ED \u00FA\u010Dinnost byla u pacient\u016F s myelodysplastick\u00FDm syndromem."@cs . . . . "The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome."@en . "11150" . . . . "L\u00E9\u010Dba p\u0159idru\u017Een\u00E9 an\u00E9mie pomoc\u00ED epoetinu alfa u r\u016Fzn\u00FDch hematologick\u00FDch onemocn\u011Bn\u00ED"@cs . "Maisnar, Vladim\u00EDr" . "Neoplasma" . "Treatment of associated anemia in different hematological disorders with epoetin alpha"@en . "5" . . "Treatment of associated anemia in different hematological disorders with epoetin alpha"@en . . "6"^^ . . . "[12679AC557C4]" . "RIV/00216208:11150/04:00004510" . . . "The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome." . . "0028-2685" . "Treatment of associated anemia in different hematological disorders with epoetin alpha" . "590746" . . "51" .